PharmaCorp Rx Inc. (TSXV:PCRX)
Canada · Delayed Price · Currency is CAD 0.4700
-0.0050 (-1.05%)
Sep 3, 2026, 2:20 PM EST
PharmaCorp Rx Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, PharmaCorp Rx stock has a consensus rating of "Strong Buy" and an average price target of $0.67. The average 1-year stock price forecast is 42.55% higher than the current stock price, while the lowest is $0.60 (+27.66%) and the highest is $0.70 (+48.94%).
Price Target: $0.67 (+42.55%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Jun 2, 2026.
Analyst Ratings
The average analyst rating for PharmaCorp Rx stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Fred Gatali Raymond James No rating | Raymond James | Buy Initiates $0.70 | Buy | Initiates | $0.70 | +48.94% | Jun 2, 2026 |
Financial Forecast
Revenue This Year
50.61M
from 20.89M
Increased by 142.22%
Revenue Next Year
98.12M
from 50.61M
Increased by 93.87%
EPS This Year
0.01
from -0.01
EPS Next Year
0.02
from 0.01
Increased by 133.30%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CAD.